TWI638829B - 分枝桿菌抗原疫苗 - Google Patents

Info

Publication number

TWI638829B

TWI638829B TW102124693A TW102124693A TWI638829B TW I638829 B TWI638829 B TW I638829B TW 102124693 A TW102124693 A TW 102124693A TW 102124693 A TW102124693 A TW 102124693A TW I638829 B TWI638829 B TW I638829B

Authority

TW

Taiwan

Prior art keywords

fusion

antigens

antigen

fusion polypeptide

mycobacterial

Prior art date

2012-07-10

Links

• Espacenet
• Global Dossier
• Discuss

• 239000000427 antigen Substances 0.000 title claims abstract description 426
• 108091007433 antigens Proteins 0.000 title claims abstract description 425
• 102000036639 antigens Human genes 0.000 title claims abstract description 425
• 229960005486 vaccine Drugs 0.000 title description 42
• 230000004927 fusion Effects 0.000 claims abstract description 586
• 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 401
• 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 282
• 239000000203 mixture Substances 0.000 claims abstract description 215
• 239000013598 vector Substances 0.000 claims abstract description 163
• 229920001184 polypeptide Polymers 0.000 claims abstract description 159
• 150000007523 nucleic acids Chemical class 0.000 claims abstract description 103
• 108020004707 nucleic acids Proteins 0.000 claims abstract description 100
• 102000039446 nucleic acids Human genes 0.000 claims abstract description 100
• 238000000034 method Methods 0.000 claims abstract description 91
• 230000001900 immune effect Effects 0.000 claims abstract description 61
• 241000186359 Mycobacterium Species 0.000 claims abstract description 58
• 230000028993 immune response Effects 0.000 claims abstract description 53
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 48
• 208000027531 mycobacterial infectious disease Diseases 0.000 claims abstract description 38
• 206010062207 Mycobacterial infection Diseases 0.000 claims abstract description 35
• -1 host cells Substances 0.000 claims abstract description 30
• 201000010099 disease Diseases 0.000 claims abstract description 26
• 238000004519 manufacturing process Methods 0.000 claims abstract description 21
• 210000004027 cell Anatomy 0.000 claims description 205
• 108090000623 proteins and genes Proteins 0.000 claims description 146
• 102000004169 proteins and genes Human genes 0.000 claims description 105
• 210000002706 plastid Anatomy 0.000 claims description 83
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 77
• 201000008827 tuberculosis Diseases 0.000 claims description 70
• 208000015181 infectious disease Diseases 0.000 claims description 68
• 101710166488 6 kDa early secretory antigenic target Proteins 0.000 claims description 47
• 239000002245 particle Substances 0.000 claims description 37
• 238000011282 treatment Methods 0.000 claims description 34
• 241000700605 Viruses Species 0.000 claims description 33
• 230000003053 immunization Effects 0.000 claims description 32
• 238000002649 immunization Methods 0.000 claims description 31
• 238000000338 in vitro Methods 0.000 claims description 29
• 239000013603 viral vector Substances 0.000 claims description 26
• 241000187479 Mycobacterium tuberculosis Species 0.000 claims description 25
• 241000588724 Escherichia coli Species 0.000 claims description 23
• 239000003999 initiator Substances 0.000 claims description 23
• 238000011534 incubation Methods 0.000 claims description 20
• 241000701161 unidentified adenovirus Species 0.000 claims description 18
• 239000002253 acid Substances 0.000 claims description 17
• 230000002458 infectious effect Effects 0.000 claims description 17
• 239000003814 drug Substances 0.000 claims description 16
• 230000007420 reactivation Effects 0.000 claims description 14
• 101100103958 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) Rv1733c gene Proteins 0.000 claims description 13
• 241000700618 Vaccinia virus Species 0.000 claims description 11
• 238000002512 chemotherapy Methods 0.000 claims description 11
• 101100351796 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) pfkB gene Proteins 0.000 claims description 10
• 230000001580 bacterial effect Effects 0.000 claims description 10
• 241000186366 Mycobacterium bovis Species 0.000 claims description 9
• 230000003115 biocidal effect Effects 0.000 claims description 9
• 229940044683 chemotherapy drug Drugs 0.000 claims description 9
• 208000032420 Latent Infection Diseases 0.000 claims description 8
• 208000037771 disease arising from reactivation of latent virus Diseases 0.000 claims description 8
• 239000013589 supplement Substances 0.000 claims description 8
• 241000283707 Capra Species 0.000 claims description 7
• 241000712079 Measles morbillivirus Species 0.000 claims description 7
• 241001467552 Mycobacterium bovis BCG Species 0.000 claims description 6
• 241000186781 Listeria Species 0.000 claims description 5
• 230000005867 T cell response Effects 0.000 claims description 5
• 230000002950 deficient Effects 0.000 claims description 5
• 239000003937 drug carrier Substances 0.000 claims description 5
• 230000012010 growth Effects 0.000 claims description 5
• 230000002265 prevention Effects 0.000 claims description 5
• 241000187919 Mycobacterium microti Species 0.000 claims description 4
• 239000002246 antineoplastic agent Substances 0.000 claims description 4
• 238000004113 cell culture Methods 0.000 claims description 4
• 238000012258 culturing Methods 0.000 claims description 4
• 230000001568 sexual effect Effects 0.000 claims description 4
• 230000000638 stimulation Effects 0.000 claims description 4
• 241001467553 Mycobacterium africanum Species 0.000 claims description 3
• 241000589516 Pseudomonas Species 0.000 claims description 3
• 241000607142 Salmonella Species 0.000 claims description 3
• 241000710929 Alphavirus Species 0.000 claims description 2
• 241000193830 Bacillus <bacterium> Species 0.000 claims description 2
• 241001312372 Mycobacterium canettii Species 0.000 claims description 2
• 241000211133 Mycobacterium caprae Species 0.000 claims description 2
• 125000003277 amino group Chemical group 0.000 claims description 2
• 239000012228 culture supernatant Substances 0.000 claims description 2
• 239000006260 foam Substances 0.000 claims description 2
• 230000001575 pathological effect Effects 0.000 claims description 2
• 238000002360 preparation method Methods 0.000 claims description 2
• 241001529453 unidentified herpesvirus Species 0.000 claims description 2
• 241001430294 unidentified retrovirus Species 0.000 claims description 2
• 101710088334 Diacylglycerol acyltransferase/mycolyltransferase Ag85B Proteins 0.000 claims 13
• 241000178270 Canarypox virus Species 0.000 claims 1
• 201000006082 Chickenpox Diseases 0.000 claims 1
• 241000186660 Lactobacillus Species 0.000 claims 1
• 206010046980 Varicella Diseases 0.000 claims 1
• 241000711975 Vesicular stomatitis virus Species 0.000 claims 1
• 229940039696 lactobacillus Drugs 0.000 claims 1
• 238000001514 detection method Methods 0.000 abstract description 21
• 239000003153 chemical reaction reagent Substances 0.000 abstract description 12
• 230000001939 inductive effect Effects 0.000 abstract description 6
• 230000004936 stimulating effect Effects 0.000 abstract description 3
• 101150087129 mtb gene Proteins 0.000 description 190
• 241000699670 Mus sp. Species 0.000 description 103
• 235000018102 proteins Nutrition 0.000 description 100
• 235000001014 amino acid Nutrition 0.000 description 91
• 229940024606 amino acid Drugs 0.000 description 90
• 150000001413 amino acids Chemical class 0.000 description 90
• 230000014509 gene expression Effects 0.000 description 84
• 238000012360 testing method Methods 0.000 description 69
• 230000004044 response Effects 0.000 description 51
• 238000002347 injection Methods 0.000 description 43
• 239000007924 injection Substances 0.000 description 43
• 230000001105 regulatory effect Effects 0.000 description 41
• 125000003729 nucleotide group Chemical group 0.000 description 38
• 239000002773 nucleotide Substances 0.000 description 37
• 239000012071 phase Substances 0.000 description 37
• 239000012634 fragment Substances 0.000 description 35
• 230000001086 cytosolic effect Effects 0.000 description 27
• 239000000047 product Substances 0.000 description 27
• 230000005847 immunogenicity Effects 0.000 description 26
• 241001465754 Metazoa Species 0.000 description 24
• 230000004048 modification Effects 0.000 description 24
• 238000012986 modification Methods 0.000 description 24
• 238000003752 polymerase chain reaction Methods 0.000 description 24
• 210000004899 c-terminal region Anatomy 0.000 description 23
• 238000010276 construction Methods 0.000 description 23
• 238000006243 chemical reaction Methods 0.000 description 22
• 239000000463 material Substances 0.000 description 21
• 239000012528 membrane Substances 0.000 description 21
• 239000013615 primer Substances 0.000 description 21
• 239000002987 primer (paints) Substances 0.000 description 21
• 238000001262 western blot Methods 0.000 description 21
• NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 20
• 238000013461 design Methods 0.000 description 20
• 230000000694 effects Effects 0.000 description 20
• 230000003612 virological effect Effects 0.000 description 20
• 238000004458 analytical method Methods 0.000 description 19
• 239000013642 negative control Substances 0.000 description 18
• 102000004190 Enzymes Human genes 0.000 description 17
• 108090000790 Enzymes Proteins 0.000 description 17
• 239000013592 cell lysate Substances 0.000 description 17
• 229940088598 enzyme Drugs 0.000 description 17
• 108020001507 fusion proteins Proteins 0.000 description 16
• 102000037865 fusion proteins Human genes 0.000 description 16
• 108091008146 restriction endonucleases Proteins 0.000 description 16
• 241000894006 Bacteria Species 0.000 description 15
• 239000013543 active substance Substances 0.000 description 15
• 230000001681 protective effect Effects 0.000 description 15
• 102100038895 Myc proto-oncogene protein Human genes 0.000 description 14
• 241000283973 Oryctolagus cuniculus Species 0.000 description 14
• 210000001744 T-lymphocyte Anatomy 0.000 description 14
• 208000035475 disorder Diseases 0.000 description 14
• 229940079593 drug Drugs 0.000 description 14
• 238000011156 evaluation Methods 0.000 description 14
• 230000006870 function Effects 0.000 description 14
• 230000036039 immunity Effects 0.000 description 14
• 239000010410 layer Substances 0.000 description 14
• 238000000746 purification Methods 0.000 description 14
• 238000011084 recovery Methods 0.000 description 14
• 108020004705 Codon Proteins 0.000 description 13
• 230000027455 binding Effects 0.000 description 13
• 210000000170 cell membrane Anatomy 0.000 description 13
• 230000002209 hydrophobic effect Effects 0.000 description 13
• 210000002966 serum Anatomy 0.000 description 13
• 101710135898 Myc proto-oncogene protein Proteins 0.000 description 12
• 230000024932 T cell mediated immunity Effects 0.000 description 12
• 101710150448 Transcriptional regulator Myc Proteins 0.000 description 12
• 238000005516 engineering process Methods 0.000 description 12
• 241000894007 species Species 0.000 description 12
• 125000000539 amino acid group Chemical group 0.000 description 11
• 239000003242 anti bacterial agent Substances 0.000 description 11
• 230000003197 catalytic effect Effects 0.000 description 11
• 238000012217 deletion Methods 0.000 description 11
• 238000002744 homologous recombination Methods 0.000 description 11
• 230000006801 homologous recombination Effects 0.000 description 11
• 238000012216 screening Methods 0.000 description 11
• 108010076504 Protein Sorting Signals Proteins 0.000 description 10
• 108700005078 Synthetic Genes Proteins 0.000 description 10
• 238000004873 anchoring Methods 0.000 description 10
• 229940088710 antibiotic agent Drugs 0.000 description 10
• 230000037430 deletion Effects 0.000 description 10
• 108010074032 HLA-A2 Antigen Proteins 0.000 description 9
• 241000699666 Mus <mouse, genus> Species 0.000 description 9
• 239000002609 medium Substances 0.000 description 9
• 208000024891 symptom Diseases 0.000 description 9
• 238000012546 transfer Methods 0.000 description 9
• 102000025850 HLA-A2 Antigen Human genes 0.000 description 8
• 101000900206 Hantaan virus (strain 76-118) Envelopment polyprotein Proteins 0.000 description 8
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 8
• 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 8
• 239000002671 adjuvant Substances 0.000 description 8
• 239000012472 biological sample Substances 0.000 description 8
• 230000015572 biosynthetic process Effects 0.000 description 8
• 238000007418 data mining Methods 0.000 description 8
• 238000003780 insertion Methods 0.000 description 8
• 230000037431 insertion Effects 0.000 description 8
• 238000013507 mapping Methods 0.000 description 8
• 230000035772 mutation Effects 0.000 description 8
• 108040007629 peroxidase activity proteins Proteins 0.000 description 8
• 102000013415 peroxidase activity proteins Human genes 0.000 description 8
• 230000010076 replication Effects 0.000 description 8
• 239000000243 solution Substances 0.000 description 8
• 108091026890 Coding region Proteins 0.000 description 7
• 102000004127 Cytokines Human genes 0.000 description 7
• 108090000695 Cytokines Proteins 0.000 description 7
• 241000701022 Cytomegalovirus Species 0.000 description 7
• 101100239628 Danio rerio myca gene Proteins 0.000 description 7
• 101710088335 Diacylglycerol acyltransferase/mycolyltransferase Ag85A Proteins 0.000 description 7
• 241000725303 Human immunodeficiency virus Species 0.000 description 7
• 102000008070 Interferon-gamma Human genes 0.000 description 7
• 108010074328 Interferon-gamma Proteins 0.000 description 7
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
• 230000008901 benefit Effects 0.000 description 7
• 230000005965 immune activity Effects 0.000 description 7
• 229960003130 interferon gamma Drugs 0.000 description 7
• 238000007918 intramuscular administration Methods 0.000 description 7
• 230000001788 irregular Effects 0.000 description 7
• 230000001404 mediated effect Effects 0.000 description 7
• 238000003786 synthesis reaction Methods 0.000 description 7
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
• 108700010070 Codon Usage Proteins 0.000 description 6
• 241000282412 Homo Species 0.000 description 6
• 108091028043 Nucleic acid sequence Proteins 0.000 description 6
• 241000711841 Rabies virus ERA Species 0.000 description 6
• 206010046865 Vaccinia virus infection Diseases 0.000 description 6
• 210000004369 blood Anatomy 0.000 description 6
• 239000008280 blood Substances 0.000 description 6
• 230000001413 cellular effect Effects 0.000 description 6
• 210000000805 cytoplasm Anatomy 0.000 description 6
• 230000003247 decreasing effect Effects 0.000 description 6
• 238000001962 electrophoresis Methods 0.000 description 6
• 239000002158 endotoxin Substances 0.000 description 6
• 239000012535 impurity Substances 0.000 description 6
• 230000001965 increasing effect Effects 0.000 description 6
• 210000004072 lung Anatomy 0.000 description 6
• 230000000717 retained effect Effects 0.000 description 6
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 6
• 210000001519 tissue Anatomy 0.000 description 6
• 231100000331 toxic Toxicity 0.000 description 6
• 230000002588 toxic effect Effects 0.000 description 6
• 238000013519 translation Methods 0.000 description 6
• 230000014616 translation Effects 0.000 description 6
• 208000007089 vaccinia Diseases 0.000 description 6
• 238000002965 ELISA Methods 0.000 description 5
• 230000004913 activation Effects 0.000 description 5
• 238000007792 addition Methods 0.000 description 5
• 238000010171 animal model Methods 0.000 description 5
• 239000000872 buffer Substances 0.000 description 5
• 230000036755 cellular response Effects 0.000 description 5
• 238000011161 development Methods 0.000 description 5
• 230000018109 developmental process Effects 0.000 description 5
• 238000010790 dilution Methods 0.000 description 5
• 239000012895 dilution Substances 0.000 description 5
• 230000001976 improved effect Effects 0.000 description 5
• 210000000056 organ Anatomy 0.000 description 5
• 239000002195 soluble material Substances 0.000 description 5
• 239000007858 starting material Substances 0.000 description 5
• 239000006228 supernatant Substances 0.000 description 5
• 238000013518 transcription Methods 0.000 description 5
• 230000035897 transcription Effects 0.000 description 5
• 238000002255 vaccination Methods 0.000 description 5
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 4
• LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 4
• 241000287828 Gallus gallus Species 0.000 description 4
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
• 201000005505 Measles Diseases 0.000 description 4
• 101100361228 Micrococcus luteus rpf gene Proteins 0.000 description 4
• 101001057048 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) ESAT-6-like protein EsxB Proteins 0.000 description 4
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 4
• 229940079156 Proteasome inhibitor Drugs 0.000 description 4
• 108010009736 Protein Hydrolysates Proteins 0.000 description 4
• 101900083372 Rabies virus Glycoprotein Proteins 0.000 description 4
• 108020004440 Thymidine kinase Proteins 0.000 description 4
• 208000036981 active tuberculosis Diseases 0.000 description 4
• 230000033228 biological regulation Effects 0.000 description 4
• 239000000969 carrier Substances 0.000 description 4
• 210000003527 eukaryotic cell Anatomy 0.000 description 4
• 239000013604 expression vector Substances 0.000 description 4
• 230000002068 genetic effect Effects 0.000 description 4
• 230000028996 humoral immune response Effects 0.000 description 4
• FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
• 238000001727 in vivo Methods 0.000 description 4
• 239000002198 insoluble material Substances 0.000 description 4
• 239000003550 marker Substances 0.000 description 4
• 238000005259 measurement Methods 0.000 description 4
• 108020004999 messenger RNA Proteins 0.000 description 4
• 238000005457 optimization Methods 0.000 description 4
• 244000052769 pathogen Species 0.000 description 4
• 239000003207 proteasome inhibitor Substances 0.000 description 4
• 239000003531 protein hydrolysate Substances 0.000 description 4
• 239000006152 selective media Substances 0.000 description 4
• 239000011780 sodium chloride Substances 0.000 description 4
• 210000000952 spleen Anatomy 0.000 description 4
• 210000004989 spleen cell Anatomy 0.000 description 4
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
• 239000000126 substance Substances 0.000 description 4
• 230000001225 therapeutic effect Effects 0.000 description 4
• 238000002560 therapeutic procedure Methods 0.000 description 4
• 238000001890 transfection Methods 0.000 description 4
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
• DLZKEQQWXODGGZ-KCJUWKMLSA-N 2-[[(2r)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetic acid Chemical compound OC(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 DLZKEQQWXODGGZ-KCJUWKMLSA-N 0.000 description 3
• 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 3
• 241000283690 Bos taurus Species 0.000 description 3
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
• IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical class OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 3
• CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Chemical class OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 3
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
• 206010059866 Drug resistance Diseases 0.000 description 3
• BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Chemical class OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 3
• ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
• 206010024229 Leprosy Diseases 0.000 description 3
• DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Chemical class CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 3
• 108010052285 Membrane Proteins Proteins 0.000 description 3
• 102000016943 Muramidase Human genes 0.000 description 3
• 108010014251 Muramidase Proteins 0.000 description 3
• 208000031998 Mycobacterium Infections Diseases 0.000 description 3
• 241000187480 Mycobacterium smegmatis Species 0.000 description 3
• 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 3
• 206010028980 Neoplasm Diseases 0.000 description 3
• 229930006000 Sucrose Natural products 0.000 description 3
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
• 108091008874 T cell receptors Proteins 0.000 description 3
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 3
• 102000006601 Thymidine Kinase Human genes 0.000 description 3
• 239000007983 Tris buffer Substances 0.000 description 3
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
• 239000012190 activator Substances 0.000 description 3
• 230000002238 attenuated effect Effects 0.000 description 3
• 230000009286 beneficial effect Effects 0.000 description 3
• 230000008827 biological function Effects 0.000 description 3
• 230000005540 biological transmission Effects 0.000 description 3
• 229960002685 biotin Drugs 0.000 description 3
• 235000020958 biotin Nutrition 0.000 description 3
• 239000011616 biotin Substances 0.000 description 3
• 229940098773 bovine serum albumin Drugs 0.000 description 3
• 238000004422 calculation algorithm Methods 0.000 description 3
• 230000006037 cell lysis Effects 0.000 description 3
• 238000004587 chromatography analysis Methods 0.000 description 3
• 230000000295 complement effect Effects 0.000 description 3
• 238000007796 conventional method Methods 0.000 description 3
• 230000006378 damage Effects 0.000 description 3
• 238000003745 diagnosis Methods 0.000 description 3
• 239000000539 dimer Substances 0.000 description 3
• 210000002472 endoplasmic reticulum Anatomy 0.000 description 3
• 238000002474 experimental method Methods 0.000 description 3
• 210000002950 fibroblast Anatomy 0.000 description 3
• 239000001963 growth medium Substances 0.000 description 3
• 230000008348 humoral response Effects 0.000 description 3
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
• 210000003000 inclusion body Anatomy 0.000 description 3
• 230000006698 induction Effects 0.000 description 3
• 239000004615 ingredient Substances 0.000 description 3
• 239000003112 inhibitor Substances 0.000 description 3
• 238000002955 isolation Methods 0.000 description 3
• BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 3
• 239000008101 lactose Substances 0.000 description 3
• 239000003446 ligand Substances 0.000 description 3
• 230000007774 longterm Effects 0.000 description 3
• 229960000274 lysozyme Drugs 0.000 description 3
• 239000004325 lysozyme Substances 0.000 description 3
• 235000010335 lysozyme Nutrition 0.000 description 3
• 210000001161 mammalian embryo Anatomy 0.000 description 3
• 229940126619 mouse monoclonal antibody Drugs 0.000 description 3
• PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Substances [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 3
• 238000006384 oligomerization reaction Methods 0.000 description 3
• 239000008188 pellet Substances 0.000 description 3
• 210000002381 plasma Anatomy 0.000 description 3
• 229920000642 polymer Polymers 0.000 description 3
• 230000008569 process Effects 0.000 description 3
• 238000012545 processing Methods 0.000 description 3
• 230000002829 reductive effect Effects 0.000 description 3
• 210000002345 respiratory system Anatomy 0.000 description 3
• 230000002441 reversible effect Effects 0.000 description 3
• JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 3
• 239000013049 sediment Substances 0.000 description 3
• 238000002864 sequence alignment Methods 0.000 description 3
• 238000002741 site-directed mutagenesis Methods 0.000 description 3
• 230000006641 stabilisation Effects 0.000 description 3
• 238000011105 stabilization Methods 0.000 description 3
• 238000010561 standard procedure Methods 0.000 description 3
• 238000007920 subcutaneous administration Methods 0.000 description 3
• 238000006467 substitution reaction Methods 0.000 description 3
• 239000000758 substrate Substances 0.000 description 3
• 239000005720 sucrose Substances 0.000 description 3
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
• 238000011144 upstream manufacturing Methods 0.000 description 3
• DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 3
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
• HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
• 241000272525 Anas platyrhynchos Species 0.000 description 2
• 241000271566 Aves Species 0.000 description 2
• 102100021935 C-C motif chemokine 26 Human genes 0.000 description 2
• 206010010356 Congenital anomaly Diseases 0.000 description 2
• 206010011224 Cough Diseases 0.000 description 2
• 241000196324 Embryophyta Species 0.000 description 2
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
• ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
• 102000018932 HSP70 Heat-Shock Proteins Human genes 0.000 description 2
• 108010027992 HSP70 Heat-Shock Proteins Proteins 0.000 description 2
• 108091027305 Heteroduplex Proteins 0.000 description 2
• 241000238631 Hexapoda Species 0.000 description 2
• 101000897493 Homo sapiens C-C motif chemokine 26 Proteins 0.000 description 2
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
• UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
• 206010062717 Increased upper airway secretion Diseases 0.000 description 2
• 102000015696 Interleukins Human genes 0.000 description 2
• 108010063738 Interleukins Proteins 0.000 description 2
• 238000012313 Kruskal-Wallis test Methods 0.000 description 2
• 239000012097 Lipofectamine 2000 Substances 0.000 description 2
• 241000186779 Listeria monocytogenes Species 0.000 description 2
• 241000124008 Mammalia Species 0.000 description 2
• 102000018697 Membrane Proteins Human genes 0.000 description 2
• 241000186360 Mycobacteriaceae Species 0.000 description 2
• 241000186367 Mycobacterium avium Species 0.000 description 2
• 241000186364 Mycobacterium intracellulare Species 0.000 description 2
• 101100000605 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) acg gene Proteins 0.000 description 2
• 241000187644 Mycobacterium vaccae Species 0.000 description 2
• 108091034117 Oligonucleotide Proteins 0.000 description 2
• 102000015636 Oligopeptides Human genes 0.000 description 2
• 108010038807 Oligopeptides Proteins 0.000 description 2
• 239000002033 PVDF binder Substances 0.000 description 2
• 241000282577 Pan troglodytes Species 0.000 description 2
• 108010067902 Peptide Library Proteins 0.000 description 2
• 206010036790 Productive cough Diseases 0.000 description 2
• 241000711798 Rabies lyssavirus Species 0.000 description 2
• 241000235347 Schizosaccharomyces pombe Species 0.000 description 2
• 241000242583 Scyphozoa Species 0.000 description 2
• 238000012300 Sequence Analysis Methods 0.000 description 2
• 241000700584 Simplexvirus Species 0.000 description 2
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
• 108091081024 Start codon Proteins 0.000 description 2
• 101100029402 Streptomyces coelicolor (strain ATCC BAA-471 / A3(2) / M145) pfkA2 gene Proteins 0.000 description 2
• 108090000992 Transferases Proteins 0.000 description 2
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
• 238000002835 absorbance Methods 0.000 description 2
• 239000012072 active phase Substances 0.000 description 2
• 230000002411 adverse Effects 0.000 description 2
• 238000001042 affinity chromatography Methods 0.000 description 2
• 230000003042 antagnostic effect Effects 0.000 description 2
• 230000000844 anti-bacterial effect Effects 0.000 description 2
• 230000001355 anti-mycobacterial effect Effects 0.000 description 2
• 239000003926 antimycobacterial agent Substances 0.000 description 2
• 210000003719 b-lymphocyte Anatomy 0.000 description 2
• 238000012742 biochemical analysis Methods 0.000 description 2
• 230000004071 biological effect Effects 0.000 description 2
• 230000037396 body weight Effects 0.000 description 2
• 230000015556 catabolic process Effects 0.000 description 2
• 125000002091 cationic group Chemical group 0.000 description 2
• 238000005119 centrifugation Methods 0.000 description 2
• 230000008859 change Effects 0.000 description 2
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
• 238000000576 coating method Methods 0.000 description 2
• 230000001332 colony forming effect Effects 0.000 description 2
• 239000002299 complementary DNA Substances 0.000 description 2
• 238000012937 correction Methods 0.000 description 2
• 238000004132 cross linking Methods 0.000 description 2
• 210000004748 cultured cell Anatomy 0.000 description 2
• 230000009089 cytolysis Effects 0.000 description 2
• OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
• 230000034994 death Effects 0.000 description 2
• 231100000517 death Toxicity 0.000 description 2
• 238000006731 degradation reaction Methods 0.000 description 2
• 230000003111 delayed effect Effects 0.000 description 2
• 238000003795 desorption Methods 0.000 description 2
• 239000003085 diluting agent Substances 0.000 description 2
• 238000004090 dissolution Methods 0.000 description 2
• 238000002651 drug therapy Methods 0.000 description 2
• 238000004520 electroporation Methods 0.000 description 2
• 101150079015 esxB gene Proteins 0.000 description 2
• AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 description 2
• 238000010195 expression analysis Methods 0.000 description 2
• 238000009472 formulation Methods 0.000 description 2
• 238000001415 gene therapy Methods 0.000 description 2
• 102000054766 genetic haplotypes Human genes 0.000 description 2
• 239000008103 glucose Substances 0.000 description 2
• 229930195712 glutamate Natural products 0.000 description 2
• 229940049906 glutamate Drugs 0.000 description 2
• 230000002414 glycolytic effect Effects 0.000 description 2
• 230000036541 health Effects 0.000 description 2
• 238000004128 high performance liquid chromatography Methods 0.000 description 2
• 229960002751 imiquimod Drugs 0.000 description 2
• DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 2
• 230000036737 immune function Effects 0.000 description 2
• 210000000987 immune system Anatomy 0.000 description 2
• 238000003018 immunoassay Methods 0.000 description 2
• 230000001024 immunotherapeutic effect Effects 0.000 description 2
• 238000009169 immunotherapy Methods 0.000 description 2
• 229940032219 immunotherapy vaccine Drugs 0.000 description 2
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
• 230000003993 interaction Effects 0.000 description 2
• 238000010255 intramuscular injection Methods 0.000 description 2
• 239000007927 intramuscular injection Substances 0.000 description 2
• TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 2
• JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
• 150000002597 lactoses Chemical class 0.000 description 2
• 208000033353 latent tuberculosis infection Diseases 0.000 description 2
• 230000021633 leukocyte mediated immunity Effects 0.000 description 2
• 150000002632 lipids Chemical class 0.000 description 2
• 239000002502 liposome Substances 0.000 description 2
• 239000007788 liquid Substances 0.000 description 2
• 239000006166 lysate Substances 0.000 description 2
• 238000012423 maintenance Methods 0.000 description 2
• 239000011159 matrix material Substances 0.000 description 2
• HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 2
• 239000003607 modifier Substances 0.000 description 2
• 229960000951 mycophenolic acid Drugs 0.000 description 2
• HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 2
• 210000000822 natural killer cell Anatomy 0.000 description 2
• 239000006199 nebulizer Substances 0.000 description 2
• 231100000252 nontoxic Toxicity 0.000 description 2
• 230000003000 nontoxic effect Effects 0.000 description 2
• 239000002777 nucleoside Substances 0.000 description 2
• 150000003833 nucleoside derivatives Chemical class 0.000 description 2
• 230000001717 pathogenic effect Effects 0.000 description 2
• 239000000546 pharmaceutical excipient Substances 0.000 description 2
• 208000026435 phlegm Diseases 0.000 description 2
• 108010079892 phosphoglycerol kinase Proteins 0.000 description 2
• 230000026731 phosphorylation Effects 0.000 description 2
• 238000006366 phosphorylation reaction Methods 0.000 description 2
• 239000002504 physiological saline solution Substances 0.000 description 2
• 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
• 239000013641 positive control Substances 0.000 description 2
• 231100000683 possible toxicity Toxicity 0.000 description 2
• 230000037452 priming Effects 0.000 description 2
• 108020003175 receptors Proteins 0.000 description 2
• 102000005962 receptors Human genes 0.000 description 2
• 230000009467 reduction Effects 0.000 description 2
• 239000012925 reference material Substances 0.000 description 2
• 238000011160 research Methods 0.000 description 2
• 229960001225 rifampicin Drugs 0.000 description 2
• 239000000523 sample Substances 0.000 description 2
• 230000003248 secreting effect Effects 0.000 description 2
• DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
• 239000007787 solid Substances 0.000 description 2
• 210000004988 splenocyte Anatomy 0.000 description 2
• 238000005507 spraying Methods 0.000 description 2
• 210000003802 sputum Anatomy 0.000 description 2
• 208000024794 sputum Diseases 0.000 description 2
• 238000003860 storage Methods 0.000 description 2
• 229960005322 streptomycin Drugs 0.000 description 2
• 230000004083 survival effect Effects 0.000 description 2
• 230000009885 systemic effect Effects 0.000 description 2
• 229940098465 tincture Drugs 0.000 description 2
• 230000009261 transgenic effect Effects 0.000 description 2
• 229960001005 tuberculin Drugs 0.000 description 2
• 238000012800 visualization Methods 0.000 description 2
• 229940075420 xanthine Drugs 0.000 description 2
• HDTRYLNUVZCQOY-UHFFFAOYSA-N &alpha;-D-glucopyranosyl-&alpha;-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
• DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
• OPCHFPHZPIURNA-MFERNQICSA-N (2s)-2,5-bis(3-aminopropylamino)-n-[2-(dioctadecylamino)acetyl]pentanamide Chemical compound CCCCCCCCCCCCCCCCCCN(CC(=O)NC(=O)[C@H](CCCNCCCN)NCCCN)CCCCCCCCCCCCCCCCCC OPCHFPHZPIURNA-MFERNQICSA-N 0.000 description 1
• OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
• OWMCODAXNFNLCU-UHFFFAOYSA-N 2-[[2-(1h-imidazol-5-yl)ethylamino]methyl]phenol Chemical compound OC1=CC=CC=C1CNCCC1=CN=CN1 OWMCODAXNFNLCU-UHFFFAOYSA-N 0.000 description 1
• QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
• UXVCEKRAZBZVSL-UHFFFAOYSA-N 2-pyridin-2-ylacetamide Chemical compound NC(=O)CC1=CC=CC=N1 UXVCEKRAZBZVSL-UHFFFAOYSA-N 0.000 description 1
• OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 1
• RHKWIGHJGOEUSM-UHFFFAOYSA-N 3h-imidazo[4,5-h]quinoline Chemical class C1=CN=C2C(N=CN3)=C3C=CC2=C1 RHKWIGHJGOEUSM-UHFFFAOYSA-N 0.000 description 1
• WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
• 101150096316 5 gene Proteins 0.000 description 1
• CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
• GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
• 208000030507 AIDS Diseases 0.000 description 1
• 108010022752 Acetylcholinesterase Proteins 0.000 description 1
• 102000012440 Acetylcholinesterase Human genes 0.000 description 1
• 241001156739 Actinobacteria <phylum> Species 0.000 description 1
• 241000251468 Actinopterygii Species 0.000 description 1
• 102000057234 Acyl transferases Human genes 0.000 description 1
• 108700016155 Acyl transferases Proteins 0.000 description 1
• 108700026758 Adenovirus hexon capsid Proteins 0.000 description 1
• 229920000936 Agarose Polymers 0.000 description 1
• 102000005751 Alcohol Oxidoreductases Human genes 0.000 description 1
• 108010031132 Alcohol Oxidoreductases Chemical group 0.000 description 1
• 108010053754 Aldehyde reductase Proteins 0.000 description 1
• 102100027265 Aldo-keto reductase family 1 member B1 Human genes 0.000 description 1
• 108091093088 Amplicon Proteins 0.000 description 1
• 108020005544 Antisense RNA Proteins 0.000 description 1
• 102000007592 Apolipoproteins Human genes 0.000 description 1
• 108010071619 Apolipoproteins Proteins 0.000 description 1
• 101100272719 Arabidopsis thaliana BRG3 gene Proteins 0.000 description 1
• 101001073212 Arabidopsis thaliana Peroxidase 33 Proteins 0.000 description 1
• 208000031504 Asymptomatic Infections Diseases 0.000 description 1
• 108090001008 Avidin Proteins 0.000 description 1
• 102100026189 Beta-galactosidase Human genes 0.000 description 1
• 239000002028 Biomass Substances 0.000 description 1
• 206010006049 Bovine Tuberculosis Diseases 0.000 description 1
• 102100033642 Bromodomain-containing protein 3 Human genes 0.000 description 1
• 102100037084 C4b-binding protein alpha chain Human genes 0.000 description 1
• 101710159767 C4b-binding protein alpha chain Proteins 0.000 description 1
• 241000272834 Cairina moschata Species 0.000 description 1
• 102100029968 Calreticulin Human genes 0.000 description 1
• 108090000549 Calreticulin Proteins 0.000 description 1
• 241000282472 Canis lupus familiaris Species 0.000 description 1
• 244000025254 Cannabis sativa Species 0.000 description 1
• 241000701489 Cauliflower mosaic virus Species 0.000 description 1
• 241000700198 Cavia Species 0.000 description 1
• 241000282693 Cercopithecidae Species 0.000 description 1
• 206010008479 Chest Pain Diseases 0.000 description 1
• 206010068051 Chimerism Diseases 0.000 description 1
• 229920001661 Chitosan Polymers 0.000 description 1
• 108020004638 Circular DNA Proteins 0.000 description 1
• 208000003322 Coinfection Diseases 0.000 description 1
• DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 description 1
• DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 description 1
• GSXOAOHZAIYLCY-UHFFFAOYSA-N D-F6P Natural products OCC(=O)C(O)C(O)C(O)COP(O)(O)=O GSXOAOHZAIYLCY-UHFFFAOYSA-N 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
• 230000006820 DNA synthesis Effects 0.000 description 1
• 238000009007 Diagnostic Kit Methods 0.000 description 1
• 206010061818 Disease progression Diseases 0.000 description 1
• 101710178629 ESAT-6-like protein Proteins 0.000 description 1
• 101710202081 FAD-linked sulfhydryl oxidase Proteins 0.000 description 1
• XZWYTXMRWQJBGX-VXBMVYAYSA-N FLAG peptide Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)CC1=CC=C(O)C=C1 XZWYTXMRWQJBGX-VXBMVYAYSA-N 0.000 description 1
• 208000000666 Fowlpox Diseases 0.000 description 1
• 206010064571 Gene mutation Diseases 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• 102000003886 Glycoproteins Human genes 0.000 description 1
• 108090000288 Glycoproteins Proteins 0.000 description 1
• 239000012981 Hank's balanced salt solution Substances 0.000 description 1
• 101710154606 Hemagglutinin Proteins 0.000 description 1
• 108010006464 Hemolysin Proteins Proteins 0.000 description 1
• 208000000616 Hemoptysis Diseases 0.000 description 1
• 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
• 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
• 101000871851 Homo sapiens Bromodomain-containing protein 3 Proteins 0.000 description 1
• 101001123325 Homo sapiens Peroxisome proliferator-activated receptor gamma coactivator 1-beta Proteins 0.000 description 1
• 241000598171 Human adenovirus sp. Species 0.000 description 1
• 101100321817 Human parvovirus B19 (strain HV) 7.5K gene Proteins 0.000 description 1
• 206010021143 Hypoxia Diseases 0.000 description 1
• 108010069992 IC31 adjuvant Proteins 0.000 description 1
• 108700002232 Immediate-Early Genes Proteins 0.000 description 1
• 206010061598 Immunodeficiency Diseases 0.000 description 1
• 108060003951 Immunoglobulin Proteins 0.000 description 1
• 206010062016 Immunosuppression Diseases 0.000 description 1
• 102000004877 Insulin Human genes 0.000 description 1
• 108090001061 Insulin Proteins 0.000 description 1
• 108091092195 Intron Proteins 0.000 description 1
• 241000235058 Komagataella pastoris Species 0.000 description 1
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
• 241000194036 Lactococcus Species 0.000 description 1
• 206010065048 Latent tuberculosis Diseases 0.000 description 1
• 108060001084 Luciferase Proteins 0.000 description 1
• 239000005089 Luciferase Substances 0.000 description 1
• 208000019693 Lung disease Diseases 0.000 description 1
• 239000006137 Luria-Bertani broth Substances 0.000 description 1
• 108091054437 MHC class I family Proteins 0.000 description 1
• 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
• GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 201000009906 Meningitis Diseases 0.000 description 1
• 102000003792 Metallothionein Human genes 0.000 description 1
• 108090000157 Metallothionein Proteins 0.000 description 1
• 206010072219 Mevalonic aciduria Diseases 0.000 description 1
• 241001183012 Modified Vaccinia Ankara virus Species 0.000 description 1
• 206010048723 Multiple-drug resistance Diseases 0.000 description 1
• 241001529936 Murinae Species 0.000 description 1
• 101100508544 Mus musculus Il2 gene Proteins 0.000 description 1
• 241000187474 Mycobacterium asiaticum Species 0.000 description 1
• 241000187482 Mycobacterium avium subsp. paratuberculosis Species 0.000 description 1
• 241001134667 Mycobacterium celatum Species 0.000 description 1
• 241000186365 Mycobacterium fortuitum Species 0.000 description 1
• 241001509451 Mycobacterium genavense Species 0.000 description 1
• 241001147828 Mycobacterium haemophilum Species 0.000 description 1
• 241000186363 Mycobacterium kansasii Species 0.000 description 1
• 241000186362 Mycobacterium leprae Species 0.000 description 1
• 241000908167 Mycobacterium lepraemurium Species 0.000 description 1
• 241000187493 Mycobacterium malmoense Species 0.000 description 1
• 241000187492 Mycobacterium marinum Species 0.000 description 1
• 241000187481 Mycobacterium phlei Species 0.000 description 1
• 241001457456 Mycobacterium pinnipedii Species 0.000 description 1
• 241000187490 Mycobacterium scrofulaceum Species 0.000 description 1
• 241001147832 Mycobacterium shimoidei Species 0.000 description 1
• 241000187489 Mycobacterium simiae Species 0.000 description 1
• 241000187496 Mycobacterium szulgai Species 0.000 description 1
• 101100318482 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) Rv2005c gene Proteins 0.000 description 1
• 101100374508 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) Rv2627c gene Proteins 0.000 description 1
• 101100361215 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) rpfA gene Proteins 0.000 description 1
• 101100361221 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) rpfC gene Proteins 0.000 description 1
• 101100361226 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) rpfE gene Proteins 0.000 description 1
• 241000187917 Mycobacterium ulcerans Species 0.000 description 1
• 241000187494 Mycobacterium xenopi Species 0.000 description 1
• 101000606416 Mycolicibacterium smegmatis (strain ATCC 700084 / mc(2)155) Acyltransferase PE Proteins 0.000 description 1
• CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
• 101800000597 N-terminal peptide Proteins 0.000 description 1
• 102400000108 N-terminal peptide Human genes 0.000 description 1
• 108700019961 Neoplasm Genes Proteins 0.000 description 1
• 102000048850 Neoplasm Genes Human genes 0.000 description 1
• 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
• 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
• 238000012408 PCR amplification Methods 0.000 description 1
• 241000711504 Paramyxoviridae Species 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 229930182555 Penicillin Natural products 0.000 description 1
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
• 108091005804 Peptidases Proteins 0.000 description 1
• 102000035195 Peptidases Human genes 0.000 description 1
• 108010056995 Perforin Proteins 0.000 description 1
• 102000004503 Perforin Human genes 0.000 description 1
• 102100028961 Peroxisome proliferator-activated receptor gamma coactivator 1-beta Human genes 0.000 description 1
• 102000012434 Phosphofructokinase-2 Human genes 0.000 description 1
• 108010022678 Phosphofructokinase-2 Proteins 0.000 description 1
• 102000001105 Phosphofructokinases Human genes 0.000 description 1
• 108010069341 Phosphofructokinases Proteins 0.000 description 1
• 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 1
• 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 1
• 108091000080 Phosphotransferase Proteins 0.000 description 1
• 229920001100 Polydextrose Polymers 0.000 description 1
• DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 1
• 229920002873 Polyethylenimine Polymers 0.000 description 1
• 101800001357 Potential peptide Proteins 0.000 description 1
• 102400000745 Potential peptide Human genes 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• 241000982698 Prorodonopsis coli Species 0.000 description 1
• 101710176177 Protein A56 Proteins 0.000 description 1
• 102000001253 Protein Kinase Human genes 0.000 description 1
• 108010026552 Proteome Proteins 0.000 description 1
• 206010037660 Pyrexia Diseases 0.000 description 1
• 206010037742 Rabies Diseases 0.000 description 1
• 241000700159 Rattus Species 0.000 description 1
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
• 108700005075 Regulator Genes Proteins 0.000 description 1
• 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
• PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
• 102000012479 Serine Proteases Human genes 0.000 description 1
• 108010022999 Serine Proteases Proteins 0.000 description 1
• 108010090804 Streptavidin Proteins 0.000 description 1
• 102000017952 Sugar transport proteins Human genes 0.000 description 1
• 108050007025 Sugar transport proteins Proteins 0.000 description 1
• 108010008038 Synthetic Vaccines Proteins 0.000 description 1
• 230000006052 T cell proliferation Effects 0.000 description 1
• 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
• 108700026226 TATA Box Proteins 0.000 description 1
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
• 239000004473 Threonine Substances 0.000 description 1
• IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
• 241000723873 Tobacco mosaic virus Species 0.000 description 1
• 102000002689 Toll-like receptor Human genes 0.000 description 1
• 108020000411 Toll-like receptor Proteins 0.000 description 1
• 102000004357 Transferases Human genes 0.000 description 1
• HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
• 102000004142 Trypsin Human genes 0.000 description 1
• 108090000631 Trypsin Proteins 0.000 description 1
• 108090000848 Ubiquitin Proteins 0.000 description 1
• 102000044159 Ubiquitin Human genes 0.000 description 1
• 208000025865 Ulcer Diseases 0.000 description 1
• 108010046334 Urease Proteins 0.000 description 1
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
• 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
• 208000036142 Viral infection Diseases 0.000 description 1
• 238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
• HIHOWBSBBDRPDW-PTHRTHQKSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] n-[2-(dimethylamino)ethyl]carbamate Chemical compound C1C=C2C[C@@H](OC(=O)NCCN(C)C)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HIHOWBSBBDRPDW-PTHRTHQKSA-N 0.000 description 1
• ZWBTYMGEBZUQTK-PVLSIAFMSA-N [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,32-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-1'-(2-methylpropyl)-6,23-dioxospiro[8,33-dioxa-24,27,29-triazapentacyclo[23.6.1.14,7.05,31.026,30]tritriaconta-1(32),2,4,9,19,21,24,26,30-nonaene-28,4'-piperidine]-13-yl] acetate Chemical compound CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c4NC5(CCN(CC(C)C)CC5)N=c4c(=NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C ZWBTYMGEBZUQTK-PVLSIAFMSA-N 0.000 description 1
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
• HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
• 239000003070 absorption delaying agent Substances 0.000 description 1
• 238000010521 absorption reaction Methods 0.000 description 1
• 230000021736 acetylation Effects 0.000 description 1
• 238000006640 acetylation reaction Methods 0.000 description 1
• 229940022698 acetylcholinesterase Drugs 0.000 description 1
• 102000005421 acetyltransferase Human genes 0.000 description 1
• 108020002494 acetyltransferase Proteins 0.000 description 1
• 239000012042 active reagent Substances 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 230000004520 agglutination Effects 0.000 description 1
• 235000004279 alanine Nutrition 0.000 description 1
• 150000001299 aldehydes Chemical group 0.000 description 1
• HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
• HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
• WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
• 229940037003 alum Drugs 0.000 description 1
• 229960004821 amikacin Drugs 0.000 description 1
• LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
• 150000001412 amines Chemical class 0.000 description 1
• 229960004909 aminosalicylic acid Drugs 0.000 description 1
• 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
• 229960000723 ampicillin Drugs 0.000 description 1
• AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
• 230000003321 amplification Effects 0.000 description 1
• 230000003698 anagen phase Effects 0.000 description 1
• 230000003466 anti-cipated effect Effects 0.000 description 1
• 230000000840 anti-viral effect Effects 0.000 description 1
• 229940121375 antifungal agent Drugs 0.000 description 1
• 239000003429 antifungal agent Substances 0.000 description 1
• 230000000890 antigenic effect Effects 0.000 description 1
• 229910052586 apatite Inorganic materials 0.000 description 1
• 235000003704 aspartic acid Nutrition 0.000 description 1
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
• 238000000889 atomisation Methods 0.000 description 1
• 244000052616 bacterial pathogen Species 0.000 description 1
• BGWGXPAPYGQALX-ARQDHWQXSA-N beta-D-fructofuranose 6-phosphate Chemical compound OC[C@@]1(O)O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O BGWGXPAPYGQALX-ARQDHWQXSA-N 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• 108010005774 beta-Galactosidase Proteins 0.000 description 1
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
• GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
• 239000002981 blocking agent Substances 0.000 description 1
• 230000000903 blocking effect Effects 0.000 description 1
• 210000000988 bone and bone Anatomy 0.000 description 1
• 238000009395 breeding Methods 0.000 description 1
• 230000001488 breeding effect Effects 0.000 description 1
• 239000007853 buffer solution Substances 0.000 description 1
• 238000004364 calculation method Methods 0.000 description 1
• 229940023860 canarypox virus HIV vaccine Drugs 0.000 description 1
• 201000011510 cancer Diseases 0.000 description 1
• 239000004202 carbamide Substances 0.000 description 1
• 230000020411 cell activation Effects 0.000 description 1
• 239000006143 cell culture medium Substances 0.000 description 1
• 230000004663 cell proliferation Effects 0.000 description 1
• 230000007969 cellular immunity Effects 0.000 description 1
• 235000013351 cheese Nutrition 0.000 description 1
• 230000014564 chemokine production Effects 0.000 description 1
• 235000012000 cholesterol Nutrition 0.000 description 1
• 238000003776 cleavage reaction Methods 0.000 description 1
• 230000007012 clinical effect Effects 0.000 description 1
• 238000007621 cluster analysis Methods 0.000 description 1
• 230000004186 co-expression Effects 0.000 description 1
• 238000011278 co-treatment Methods 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 229940000425 combination drug Drugs 0.000 description 1
• 230000002860 competitive effect Effects 0.000 description 1
• 239000003184 complementary RNA Substances 0.000 description 1
• 238000010668 complexation reaction Methods 0.000 description 1
• 150000001875 compounds Chemical class 0.000 description 1
• 238000004590 computer program Methods 0.000 description 1
• 238000012790 confirmation Methods 0.000 description 1
• 239000000470 constituent Substances 0.000 description 1
• 230000001276 controlling effect Effects 0.000 description 1
• 230000008878 coupling Effects 0.000 description 1
• 238000010168 coupling process Methods 0.000 description 1
• 238000005859 coupling reaction Methods 0.000 description 1
• 230000037029 cross reaction Effects 0.000 description 1
• 239000013078 crystal Substances 0.000 description 1
• 238000002425 crystallisation Methods 0.000 description 1
• 230000008025 crystallization Effects 0.000 description 1
• 239000012531 culture fluid Substances 0.000 description 1
• 125000004122 cyclic group Chemical group 0.000 description 1
• 229960003077 cycloserine Drugs 0.000 description 1
• 238000004163 cytometry Methods 0.000 description 1
• 229940104302 cytosine Drugs 0.000 description 1
• 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
• 231100000135 cytotoxicity Toxicity 0.000 description 1
• 230000003013 cytotoxicity Effects 0.000 description 1
• 230000007547 defect Effects 0.000 description 1
• 230000007812 deficiency Effects 0.000 description 1
• 238000004925 denaturation Methods 0.000 description 1
• 230000036425 denaturation Effects 0.000 description 1
• 210000004443 dendritic cell Anatomy 0.000 description 1
• 238000010586 diagram Methods 0.000 description 1
• 239000000385 dialysis solution Substances 0.000 description 1
• 235000015872 dietary supplement Nutrition 0.000 description 1
• 230000029087 digestion Effects 0.000 description 1
• SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
• 230000005750 disease progression Effects 0.000 description 1
• 239000002612 dispersion medium Substances 0.000 description 1
• 238000002224 dissection Methods 0.000 description 1
• 230000006334 disulfide bridging Effects 0.000 description 1
• 239000002019 doping agent Substances 0.000 description 1
• 238000001647 drug administration Methods 0.000 description 1
• 235000013601 eggs Nutrition 0.000 description 1
• 238000007787 electrohydrodynamic spraying Methods 0.000 description 1
• 239000003480 eluent Substances 0.000 description 1
• 210000002257 embryonic structure Anatomy 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
• 230000002708 enhancing effect Effects 0.000 description 1
• 230000002255 enzymatic effect Effects 0.000 description 1
• 210000003743 erythrocyte Anatomy 0.000 description 1
• 239000003797 essential amino acid Substances 0.000 description 1
• 235000020776 essential amino acid Nutrition 0.000 description 1
• 229960000285 ethambutol Drugs 0.000 description 1
• AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 1
• 229960002001 ethionamide Drugs 0.000 description 1
• 230000000763 evoking effect Effects 0.000 description 1
• 230000007717 exclusion Effects 0.000 description 1
• 239000000284 extract Substances 0.000 description 1
• 238000000605 extraction Methods 0.000 description 1
• 238000000855 fermentation Methods 0.000 description 1
• 230000004151 fermentation Effects 0.000 description 1
• 238000001914 filtration Methods 0.000 description 1
• 239000010419 fine particle Substances 0.000 description 1
• 238000000684 flow cytometry Methods 0.000 description 1
• 238000007710 freezing Methods 0.000 description 1
• 230000008014 freezing Effects 0.000 description 1
• 229930182830 galactose Natural products 0.000 description 1
• 230000002496 gastric effect Effects 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• 238000001502 gel electrophoresis Methods 0.000 description 1
• 238000002523 gelfiltration Methods 0.000 description 1
• 238000007429 general method Methods 0.000 description 1
• 230000007614 genetic variation Effects 0.000 description 1
• 229960002989 glutamic acid Drugs 0.000 description 1
• 230000036252 glycation Effects 0.000 description 1
• 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
• 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
• 230000034659 glycolysis Effects 0.000 description 1
• 101150106093 gpt gene Proteins 0.000 description 1
• RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 1
• 230000005802 health problem Effects 0.000 description 1
• 210000002443 helper t lymphocyte Anatomy 0.000 description 1
• 239000000185 hemagglutinin Substances 0.000 description 1
• 239000003228 hemolysin Substances 0.000 description 1
• 108010037896 heparin-binding hemagglutinin Proteins 0.000 description 1
• 238000000703 high-speed centrifugation Methods 0.000 description 1
• 239000000710 homodimer Substances 0.000 description 1
• 239000005556 hormone Substances 0.000 description 1
• 229940088597 hormone Drugs 0.000 description 1
• 210000005260 human cell Anatomy 0.000 description 1
• XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
• 230000007954 hypoxia Effects 0.000 description 1
• 210000002865 immune cell Anatomy 0.000 description 1
• 238000010166 immunofluorescence Methods 0.000 description 1
• 230000002163 immunogen Effects 0.000 description 1
• 102000018358 immunoglobulin Human genes 0.000 description 1
• 230000016784 immunoglobulin production Effects 0.000 description 1
• 229940072221 immunoglobulins Drugs 0.000 description 1
• 239000002955 immunomodulating agent Substances 0.000 description 1
• 229940121354 immunomodulator Drugs 0.000 description 1
• 238000001114 immunoprecipitation Methods 0.000 description 1
• 239000003547 immunosorbent Substances 0.000 description 1
• 230000001506 immunosuppresive effect Effects 0.000 description 1
• 238000002650 immunosuppressive therapy Methods 0.000 description 1
• 230000001771 impaired effect Effects 0.000 description 1
• 230000006872 improvement Effects 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• 239000000411 inducer Substances 0.000 description 1
• 208000000509 infertility Diseases 0.000 description 1
• 230000036512 infertility Effects 0.000 description 1
• 208000021267 infertility disease Diseases 0.000 description 1
• 230000002401 inhibitory effect Effects 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 239000000976 ink Substances 0.000 description 1
• 230000015788 innate immune response Effects 0.000 description 1
• 229940125396 insulin Drugs 0.000 description 1
• 239000011229 interlayer Substances 0.000 description 1
• 229940047122 interleukins Drugs 0.000 description 1
• 230000016507 interphase Effects 0.000 description 1
• 238000001361 intraarterial administration Methods 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 229940065638 intron a Drugs 0.000 description 1
• 238000011835 investigation Methods 0.000 description 1
• 238000005342 ion exchange Methods 0.000 description 1
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• ZKLLSNQJRLJIGT-UYFOZJQFSA-N keto-D-fructose 1-phosphate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)COP(O)(O)=O ZKLLSNQJRLJIGT-UYFOZJQFSA-N 0.000 description 1
• 238000002372 labelling Methods 0.000 description 1
• 235000014655 lactic acid Nutrition 0.000 description 1
• 239000004310 lactic acid Substances 0.000 description 1
• 230000003902 lesion Effects 0.000 description 1
• 230000004576 lipid-binding Effects 0.000 description 1
• 230000029226 lipidation Effects 0.000 description 1
• 229920006008 lipopolysaccharide Polymers 0.000 description 1
• 238000004811 liquid chromatography Methods 0.000 description 1
• 230000007762 localization of cell Effects 0.000 description 1
• 210000001165 lymph node Anatomy 0.000 description 1
• 201000007227 lymph node tuberculosis Diseases 0.000 description 1
• 230000001806 lysozymelike Effects 0.000 description 1
• 230000014759 maintenance of location Effects 0.000 description 1
• 210000004962 mammalian cell Anatomy 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 244000005700 microbiome Species 0.000 description 1
• 238000000520 microinjection Methods 0.000 description 1
• 210000001589 microsome Anatomy 0.000 description 1
• 239000002480 mineral oil Substances 0.000 description 1
• 235000010446 mineral oil Nutrition 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 238000010172 mouse model Methods 0.000 description 1
• 238000002887 multiple sequence alignment Methods 0.000 description 1
• 238000002703 mutagenesis Methods 0.000 description 1
• 231100000350 mutagenesis Toxicity 0.000 description 1
• 239000002105 nanoparticle Substances 0.000 description 1
• 210000000581 natural killer T-cell Anatomy 0.000 description 1
• 229910052759 nickel Inorganic materials 0.000 description 1
• 206010029410 night sweats Diseases 0.000 description 1
• 230000036565 night sweats Effects 0.000 description 1
• 238000003199 nucleic acid amplification method Methods 0.000 description 1
• 235000015097 nutrients Nutrition 0.000 description 1
• 229960001699 ofloxacin Drugs 0.000 description 1
• 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 230000003204 osmotic effect Effects 0.000 description 1
• 230000002018 overexpression Effects 0.000 description 1
• 229910052760 oxygen Inorganic materials 0.000 description 1
• 239000001301 oxygen Substances 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 230000007918 pathogenicity Effects 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• 230000035515 penetration Effects 0.000 description 1
• 229940049954 penicillin Drugs 0.000 description 1
• VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 description 1
• 230000010412 perfusion Effects 0.000 description 1
• 230000002085 persistent effect Effects 0.000 description 1
• 239000008194 pharmaceutical composition Substances 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• 239000008363 phosphate buffer Substances 0.000 description 1
• 102000020233 phosphotransferase Human genes 0.000 description 1
• 229920002851 polycationic polymer Polymers 0.000 description 1
• 239000001259 polydextrose Substances 0.000 description 1
• 229940035035 polydextrose Drugs 0.000 description 1
• 229920001601 polyetherimide Polymers 0.000 description 1
• 229920002704 polyhistidine Polymers 0.000 description 1
• 229920000193 polymethacrylate Polymers 0.000 description 1
• 102000054765 polymorphisms of proteins Human genes 0.000 description 1
• 108091033319 polynucleotide Proteins 0.000 description 1
• 102000040430 polynucleotide Human genes 0.000 description 1
• 239000002157 polynucleotide Substances 0.000 description 1
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
• 229920000053 polysorbate 80 Polymers 0.000 description 1
• 230000004481 post-translational protein modification Effects 0.000 description 1
• 244000144977 poultry Species 0.000 description 1
• 239000000843 powder Substances 0.000 description 1
• 244000062645 predators Species 0.000 description 1
• 230000003449 preventive effect Effects 0.000 description 1
• 210000001236 prokaryotic cell Anatomy 0.000 description 1
• 230000009465 prokaryotic expression Effects 0.000 description 1
• 230000002062 proliferating effect Effects 0.000 description 1
• 230000001737 promoting effect Effects 0.000 description 1
• 230000000644 propagated effect Effects 0.000 description 1
• 230000000069 prophylactic effect Effects 0.000 description 1
• 235000019833 protease Nutrition 0.000 description 1
• 108020001580 protein domains Proteins 0.000 description 1
• 230000012846 protein folding Effects 0.000 description 1
• 230000004853 protein function Effects 0.000 description 1
• 108060006633 protein kinase Proteins 0.000 description 1
• 238000001742 protein purification Methods 0.000 description 1
• 230000006432 protein unfolding Effects 0.000 description 1
• 230000006337 proteolytic cleavage Effects 0.000 description 1
• 101150088899 pstS1 gene Proteins 0.000 description 1
• 238000004080 punching Methods 0.000 description 1
• 238000011002 quantification Methods 0.000 description 1
• 238000000163 radioactive labelling Methods 0.000 description 1
• 239000012857 radioactive material Substances 0.000 description 1
• 238000003127 radioimmunoassay Methods 0.000 description 1
• ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
• 230000036647 reaction Effects 0.000 description 1
• 238000003259 recombinant expression Methods 0.000 description 1
• 229940124551 recombinant vaccine Drugs 0.000 description 1
• 230000010666 regulation of catalytic activity Effects 0.000 description 1
• 230000008521 reorganization Effects 0.000 description 1
• 230000003362 replicative effect Effects 0.000 description 1
• 239000011347 resin Substances 0.000 description 1
• 229920005989 resin Polymers 0.000 description 1
• 229960000885 rifabutin Drugs 0.000 description 1
• WDZCUPBHRAEYDL-GZAUEHORSA-N rifapentine Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N(CC1)CCN1C1CCCC1 WDZCUPBHRAEYDL-GZAUEHORSA-N 0.000 description 1
• 229960002599 rifapentine Drugs 0.000 description 1
• 210000003296 saliva Anatomy 0.000 description 1
• 239000012723 sample buffer Substances 0.000 description 1
• 229930182490 saponin Natural products 0.000 description 1
• 150000007949 saponins Chemical class 0.000 description 1
• 235000017709 saponins Nutrition 0.000 description 1
• 230000007017 scission Effects 0.000 description 1
• 238000006748 scratching Methods 0.000 description 1
• 230000002393 scratching effect Effects 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 238000013207 serial dilution Methods 0.000 description 1
• 235000004400 serine Nutrition 0.000 description 1
• 238000009589 serological test Methods 0.000 description 1
• 208000012201 sexual and gender identity disease Diseases 0.000 description 1
• 208000015891 sexual disease Diseases 0.000 description 1
• 238000010008 shearing Methods 0.000 description 1
• 239000013605 shuttle vector Substances 0.000 description 1
• QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
• 229960002930 sirolimus Drugs 0.000 description 1
• 210000002027 skeletal muscle Anatomy 0.000 description 1
• 235000017557 sodium bicarbonate Nutrition 0.000 description 1
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
• 229940054269 sodium pyruvate Drugs 0.000 description 1
• 239000002904 solvent Substances 0.000 description 1
• 125000006850 spacer group Chemical group 0.000 description 1
• 238000011895 specific detection Methods 0.000 description 1
• 238000001694 spray drying Methods 0.000 description 1
• 238000011301 standard therapy Methods 0.000 description 1
• 238000007619 statistical method Methods 0.000 description 1
• 238000000528 statistical test Methods 0.000 description 1
• 208000003265 stomatitis Diseases 0.000 description 1
• 238000010254 subcutaneous injection Methods 0.000 description 1
• 239000007929 subcutaneous injection Substances 0.000 description 1
• 230000000153 supplemental effect Effects 0.000 description 1
• 230000001502 supplementing effect Effects 0.000 description 1
• 230000008093 supporting effect Effects 0.000 description 1
• 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 230000002459 sustained effect Effects 0.000 description 1
• 238000013268 sustained release Methods 0.000 description 1
• 239000012730 sustained-release form Substances 0.000 description 1
• 238000007910 systemic administration Methods 0.000 description 1
• 238000012353 t test Methods 0.000 description 1
• 238000004885 tandem mass spectrometry Methods 0.000 description 1
• 229960000814 tetanus toxoid Drugs 0.000 description 1
• 229940126585 therapeutic drug Drugs 0.000 description 1
• 229940021747 therapeutic vaccine Drugs 0.000 description 1
• 235000008521 threonine Nutrition 0.000 description 1
• 238000011200 topical administration Methods 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 235000013619 trace mineral Nutrition 0.000 description 1
• 239000011573 trace mineral Substances 0.000 description 1
• 230000005030 transcription termination Effects 0.000 description 1
• 238000010361 transduction Methods 0.000 description 1
• 230000026683 transduction Effects 0.000 description 1
• 239000012096 transfection reagent Substances 0.000 description 1
• 230000009466 transformation Effects 0.000 description 1
• 238000011830 transgenic mouse model Methods 0.000 description 1
• 230000001052 transient effect Effects 0.000 description 1
• 230000007704 transition Effects 0.000 description 1
• 239000012588 trypsin Substances 0.000 description 1
• 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 1
• 239000002451 tumor necrosis factor inhibitor Substances 0.000 description 1
• 231100000397 ulcer Toxicity 0.000 description 1
• 238000002604 ultrasonography Methods 0.000 description 1
• ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical class C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
• HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
• 241000701447 unidentified baculovirus Species 0.000 description 1
• 229940125575 vaccine candidate Drugs 0.000 description 1
• 238000001291 vacuum drying Methods 0.000 description 1
• 238000009777 vacuum freeze-drying Methods 0.000 description 1
• 230000006453 vascular barrier function Effects 0.000 description 1
• 229940126580 vector vaccine Drugs 0.000 description 1
• 238000012795 verification Methods 0.000 description 1
• 230000009385 viral infection Effects 0.000 description 1
• 210000002845 virion Anatomy 0.000 description 1
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
• 230000003442 weekly effect Effects 0.000 description 1
• 230000004580 weight loss Effects 0.000 description 1